Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint

Trop Med Int Health. 2016 Dec;21(12):1490-1495. doi: 10.1111/tmi.12784. Epub 2016 Oct 17.

Raffaella Ravinetto^{1

2}, Anja De Weggheleire¹, Thomas P C Dorlo^{3

4}, Sven Francque⁵, An Sokkab⁶, Corinne Pouget⁷, Bruno Meessen⁸, Patricia Tabernero⁹, Paul N Newton^{10

11

12

13}, Lut Lynen¹

¹ Clinical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium.
² Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.
³ Department Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
⁴ Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.
⁵ University of Antwerp, Antwerp, Belgium.
⁶ Sihanouk Hospital Centre of Hope, Phnom Penh, Cambodia.
⁷ QUAMED, Institute of Tropical Medicine, Antwerp, Belgium.
⁸ Public Health Department, Institute of Tropical Medicine, Antwerp, Belgium.
⁹ INSERM U 1058, Montpellier, France.
¹⁰ Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Mahosot Hospital, Vientiane, Lao PDR.
¹¹ Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, Oxford University, Oxford, UK.
¹² Worldwide Antimalarial Resistance Network, Churchill Hospital, Oxford University, Oxford, UK.
¹³ London School of Hygiene and Tropical Medicine, London, UK.

No abstract available

Keywords: access to medicines; counterfeit medicines; essential medicines; hepatitis C; quality of medicines; substandard medicines.

Publication types